01:00 PM EDT, 08/11/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lift our 12-month target by $1 to $70, a 19.1x multiple of our 2026 EPS estimate, a discount to GMED's historical forward average due to risks from weight-loss medications. We widen our 2025 EPS forecast by $0.03 to $3.22 and narrow 2026's by $0.06 to $3.66. GMED reported Q2 EPS of $0.86 vs. $0.75, beating the S&P Capital IQ consensus estimate by $0.11. Sales surged 18.4% Y/Y to $745.3M, with the U.S. market (which accounts for about 80% of total sales), growing 20.3% Y/Y, while international sales grew by 11.0%. Globus Medical's ( GMED ) gross profit margin expanded significantly to 63.3% from 55.2% in the prior-year quarter, while its adjusted gross profit margin saw a slight improvement of 20 bps Y/Y to 67.4%. GMED's Musculoskeletal Solutions segment, which includes the core spine business, showed strength and grew 19.8% Y/Y, offsetting a 4.4% decline in the smaller Enabling Technologies segment. The integration of the recently acquired Nevro Corporation is underway; we expect the acquisition to deliver synergies and be accretive in year two.